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Background and Purpose: 
123I cardiac meta-iodobenzylguanidine (MIBG), an analogue of norepinephrine, has 
been used to estimate myocardial sympathetic nerve function. We investigate whether cardiac-MIBG SPECT is 
clinically applicable in the differentiation of Parkinson’s disease (PD) from parkinsonian syndromes. 
Methods: Cardiac-MIBG scintigraphy was performed in 27 controls, in 40 patients with PD and in 52 patients 
with other parkinsonian syndromes comprising 23 with multiple system atrophy (MSA), 26 with drug-induced 
parkinsonism (DIP), and 3 with corticobasal degeneration (CBD). The heart to mediastinum (H/M) uptake ratio was 
calculated for each subjects. Patients who either had medical conditions that confused the MIBG SPECT results or 
who took medications that interfere with MIBG accumulation were excluded from the study. 
Results: Both early and delayed H/M ratios were in patients with PD significantly lower than in controls (early, 
1.34±0.15 vs 1.79±0.19; delayed, 1.29±0.15 vs 2.06±0.29, p<0.001). In patients with PD, both early and delayed 
H/M ratios were significantly lower than those in patients with MSA (early, 1.68±0.23; delayed, 1.80±0.34, p<0.001), 
DIP (early, 1.83±0.24; delayed, 2.07±0.4, p<0.001), or CBD (early, 1.85±0.01; delayed, 1.99±0.19, p<0.001). Two 
patients with DIP, who were within the range of patients with PD, showed clinically similar courses of PD. 
Conclusions: This study demonstrates that cardiac-MIBG is a clinically powerful tools to differentiate PD from 
other parkinsonian syndromes.
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INTRODUCTION
Although the diagnosis of Parkinson’s disease (PD) 
appears simple, a recent clinicopathological study found 
that up to 25% diagnoses in patients with PD made by 
nonspecialists were incorrect according to the post-
mortem pathological results.
1,2 Most misdiagnoses 
involved the differentiation between PD and atypical 
parkinsonism. In atypical parkinsonian syndrome, this 
disease generally progresses rapidly, responds poorly to 
dopaminergic agents, and has additional symptoms, such 
as autonomic symptoms, cerebellar ataxia, limited 
vertical eye movements, cortical sensory disturbances, 
and pyramidal symptoms. Atypical parkinsonism 
includes dementia with Lewy bodies, multiple system 
atrophy (MSA), progressive supranuclear palsy (PSP), 
and corticobasal degeneration (CBD). It is important to Journal of Clinical Neurology: Vol. 2, No. 1, 2006
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Figure 1. Definition of regions of interest (ROI) on an anterior
planar image of a control subject. Rectangular ROIs are drawn 
on the heart (1) and mediastinum (2) for early (A) and delayed
(B) images. Cardiac meta-iodobenzylguanidine (MIBG) uptake is
assessed using the heart-to-mediastinum (H/M) activity ratio that
determines the average count per  pixel in the ROI. 
differentiate atypical parkinsonism from PD to make an 
accurate prognosis and devise a proper treatment plan 
without unnecessary costs or surgery.
The clinical manifestations of drug-induced parkin-
sonism (DIP), which constitutes 15-60% of parkinsonism 
cases, are very similar to those of PD. Usually, the 
parkinsonian symptoms resolve within a few weeks after 
the patient stops taking the offending drug. Since several 
irreversible cases of DIP have been reported,
3,4 and Burn 
and Brooks showed that there was dysfunction of the 
nigrostriatal pathway in one-third of DIP cases using 
18F-dopa PET,
5 we believe that in these cases, the 
offending drug revealed PD at a preclinical stage.
Since 
123I-meta-iodobenzylguanidine (MIBG) is a 
sympathomimetic, it is taken up by the norepinephrine 
transporter, stored in vesicles at postganglionic sympa-
thetic nerve terminals, and released into the synapse by 
nerve stimuli. Whereas norepinephrine is degraded after 
release by monoamine oxidase or catechol-O- 
methyltransferase, MIBG is unaffected, allowing visuali-
zation of the function of sympathetic nerves noninva-
sively.
6-9 The degree of MIBG uptake reflects whether 
the postganglionic sympathetic nerve is damaged. 
Several studies using this technique showed that 
123I-MIBG is useful for differentiating PD from atypical 
parkinsonism, especially MSA.
10-13 
In this study, we compared the results of cardiac- 
MIBG imaging in patients with MSA, CBD, and DIP to 
demonstrate its usefulness in differentiating PD from 
atypical parkinsonism.
MATERIALS AND METHODS
1. Patients
This study examined 119 patients and controls. PD, 
MSA, and CBD were diagnosed using both the United 
Kingdom Parkinson’s Disease Society Brain Bank 
Clinical Diagnosis Criteria
2 proposed by Gilman et al.
14 
and the criteria proposed by Boeve et al.
15 DIP was 
diagnosed using the following three criteria: 1) the 
presence of least two of the four cardinal signs (tremor, 
rigidity, bradykinesia, and impaired postural reflexes), 2) 
the absence of a history of extrapyramidal disorders 
before treatment with the offending drug, and 3) the 
onset of symptoms in the course of treatment with the 
offending drug. The severity of symptoms was classified 
according to Hoehn and Yahr (H&Y).
16 The clinical 
stage of DIP was assessed at the initial evaluation and 
6 months after withdrawal of the offending drug.
The patients had no history of exposure to either 
neuroleptic drugs or any other cause of secondary 
parkinsonism. Other exclusion criteria were spondylotic 
or vascular myelopathy, infections, gammopathies, 
dysimmune or toxic neuropathies, alcoholism, diabetes 
mellitus, or other diseases that affect the autonomic 
nervous system. None of the patients had a history of 
ischemic heart disease, especially of myocardial 
infarction, thyroid disease, arterial hypertension, or 
evidence of myocardial ischemia on electrocardiogram. 
None of the patients received any of the substances that 
are known, expected, or expected to interfere with 
123I-MIBG uptake.
The controls had no history of either ischemic heart 
disease or peripheral neuropathy, and no neurological 
symptoms. None of the controls received drugs that 
might affect the uptake of 
123I-MIBG.
2. Methods
123I-MIBG (111 mBq) was injected intravenously into 
each subject. Three hours later, the image of cardiac Shin DH, et al. Cardiac MIBG SPECT in the Differentiation of Parkinsonian Syndromes 
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Patient 
no.
Age 
(years) /
sex
Offending drug 
duration 
(months)
Initial
H&Y 
stage
Follow-up 
H&Y 
stage
Patient 
no.
Age 
(years) /
sex
Offending drug
duration 
(months)
Initial
H&Y 
stage
Follow-up 
H&Y 
stage
1
2
3
4
5
6
7
8
9
10
11
12
13
65/F
69/F
71/F
51/M
70/F
67/F
72/M
76/F
67/F
66/F
74/F
70/F
83/F
Levosulpiride (6)
Levosulpiride (10)
Levosulpiride (5)
Levosulpiride (18)
Levosulpiride (20)
Levosulpiride (46)
Levosulpiride (4)
Levosulpiride (6)
Levosulpiride (2)
Levosulpiride (10)
Levosulpiride (14)
Levosulpiride (5)
Levosulpiride (3)
2.5
2
2.5
2
3
2.5
2.5
3
2
3
3
2
2
0
0
0
0
0
1
2.5
1
0
0
0
0
0
14
15
16
17
18
19
20
21
22
23
24
25
26
76/F
68/F
71/F
64/F
68/M
73/M
60/F
41/F
68/F
65/M
64/F
72/F
66/F
Levosulpiride (8)
Levosulpiride (4)
Levosulpiride (4)
Metoclopramide (5)
Perphenazine (120)
Perphenazine (84)
Perphenazine (26)
Risperidone (5)
Risperidone (2)
Risperidone (5)
Chlorpromazine (20)
Haloperidol (5)
Cilnidipine (12)
2.5
2
2
2.5
3
2.5
2.5
5
2.5
3
4
2.5
2.5
0
0
0
0
1
0
0
1
2.5
1
1
0
0
H&Y; Hoehn and Yahr
Table 1. Demographic features in patients with drug-induced parkinsonism and the offending drugs
Figure 2. Scatter diagram of an individual H/M ratio of 123I-MIBG uptake in patients with Parkinson’s disease (PD), multiple system
atrophy (MSA), drug-induced parkinsonism (DIP), and corticobasal degeneration (CBD), compared with controls (Con). The thick line 
indicates the mean value of the H/M ratio. Panels 2A and 2B indicate early and delayed MIBG images, respectively.
uptake was taken using a dual-head γ -camera SPECT 
(MultiSPECT III; Siemens Medical Systems, Iselin, NJ, 
USA). The region of interest consisted of the entire heart 
and mediastinum in the frontal image. The ratio of 
123I-MIBG uptake in the heart to that in the mediastinum 
(H/M ratio) was calculated (Fig. 1).
3. Statistical Analysis
The results are expressed as the means±SD values. 
The chi-square test, analysis of variance (ANOVA), and 
receiver operating characteristic curve were used to 
examine the differences between groups using com-Journal of Clinical Neurology: Vol. 2, No. 1, 2006
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Figure 3. Cutoff values to discriminate between patients with PD and controls (left) in an early MIBG image, and between patients with
PD and MSA (right) in a delayed MIBG image.
mercial software (SPSS, version 12.0 and MedCalc), and 
p values less than 0.05 were considered statistically 
significant.
RESULTS
The patients included 40 indivisuals with PD (22 
females, 18 males; mean age, 64.56 years; mean 
duration of disease, 46.78±30.37 months; H & Y stage, 
2.25±0.95), 23 with MSA (10 females, 13 males; mean 
age, 57.13 years; mean duration of disease, 44.21± 
15.68 months; H & Y stage, 3.58±1.02), and 3 with 
CBD (1 female, 2 males; mean age, 68.8 years). There 
were 27 controls (15 females, 12 males; mean age, 
66.11 years). The patients with MSA were significantly 
younger than those in the other groups (p<0.05) and the 
H&Y stage was significantly lower for MSA patients 
than for PD patients (p<0.01), although there was no 
significant difference in the proportion of males and 
females. Table 1 lists details of the offending drugs 
and information on the DIP patients.
Fig. 2-A and 2-B show the respective distributions of 
the early and delayed H/M ratios of the controls and 
those within each disease subgroup. The H/M ratio in 
the early and delayed images was significantly lower in 
PD thant in the controls (early PD, 1.34±0.15 vs. 
1.79±0.19; delayed, 1.29±0.15 vs. 2.06±0.29; p<0.001). 
In addition, the H/M ratio was markedly lower in PD 
patients than in MSA patients (early, 1.68±0.23; 
delayed, 1.80±0.34; p<0.001), CBD patients (early, 
1.85±0.04; delayed, 1.99±0.19; p<0.001), and DIP 
patients (early, 1.83±0.24; delayed, 2.07±0.4; p< 
0.001). The MIBG H/M ratios did not differ 
significantly among patients with MSA, CBD, DIP, 
and controls.
The threshold values of the early and delayed H/M 
ratios that distinguished PD patients from the controls 
were 1.57 (sensitivity, 95.0%; specificity, 88.9%) and 
1.56 (sensitivity, 95.0%; specificity, 100%), respectively. 
There was no difference in the discriminating power of 
the early and delayed H/M ratios (p=0.188, 95% CI= 
-0.014 to 0.07; Fig. 3). The thresholds of the early and 
delayed H/M ratios that distinguished PD patients from 
MSA patients were 1.38 (sensitivity, 65.7%; specificity, 
95.7%) and 1.36 (sensitivity, 80.0%; specificity, 100%), 
respectively. The delayed H/M ratio was statistically 
better than the early H/M ratio (p=0.068, 95% CI= 
-0.005 to 0.138; Fig. 3).
The degree of reduced cardiac-MIBG uptake (delayed Shin DH, et al. Cardiac MIBG SPECT in the Differentiation of Parkinsonian Syndromes 
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H/M ratio minus early H/M ratio) was significantly 
higher in PD patients (-0.05±0.12) than in the controls 
(0.26±0.22;  p<0.001) and MSA patients (0.12±0.21; p 
<0.025).
Twenty-four of the 26 patients with DIP had an H/M 
ratio within 2 standard deviations of the mean, while 
two patients had values below 1.57, which was the 
borderline value between the control and PD patients, 
and fell within the range of the PD patients. The 24 
patients with DIP whose MIBG uptake was within the 
normal range showed dramatic improvement or complete 
resolution of their parkinsonism on clinical follow-up 6 
months after withdrawal of the offending drug, whereas 
the 2 DIP patients (numbers 7 and 16) whose MIBG 
uptake was significantly reduced exhibited persistent 
parkinsonism. Both of these patients responded well to 
treatment with levodopa, exhibiting improvements of 
(54% and 76% on the motor Unified Parkinson’s 
Disease Rating Scale, respectively).
DISCUSSION
In this study, the cardiac-MIBG H/M ratio of PD 
patients was reduced markedly compared with that of 
controls and was clearly different from the cardiac- 
MIBG H/M ratios in patients with MSA, CBC, and DIP. 
In addition, the two DIP patients whose H/M ratios were 
within the range of PD patients showed a clinical course 
similar to that of the PD patients, in contrast to the 
patients whose H/M ratios were normal.
When PD was defined as an early H/M ratio below 
1.57 and a delayed H/M ratio below 1.56 to discriminate 
PD from controls, the sensitivity and specificity were 
95% and 88.9% for the early H/M ratio and 95% and 
100% for the delayed H/M ratio, respectively. Although 
the late H/M ratio was more sensitive and specific, 
difference between the two ratios was not statistically 
significant (p=0.201). Therefore, for convenience, a 
diagnosis can be made using the early H/M ratio when 
the early ratio is above 1.57, in order to save the 
patients from waiting for 3h. Moreover, the threshold 
that differentiates patients with PD from those with 
MSA was an early H/M ratio of 1.38 (sensitivity, 
65.7%; specificity, 95.7) and a delay H/M ration of 1.36 
(sensitivity, 80.0%; specificity, 100%). The delayed H/M 
ratio was marginally more sensitive and specific 
compared with the early H/M ratio (p=0.068).
MIBG is not metabolized by catechol-O-methyl-
transferase or monoamine oxidase.
17 Two uptake systems 
for MIBG have been identified in adrenergic tissues. 
The first system involves diffusion in non-neuronal and 
neuronal tissues. Scanning during the first 15 min 
postinjection mainly reflects the greater influx of MIBG 
into the extraneural space in myocardial tissue, rather 
than into the neuronal component. The second system is 
uptake by neuronal tissue using the sodium and ATP- 
dependent transporter at low concentrations. The 
neuronal accumulation of MIBG reaches its maximum at 
3-4 h after injection, so a delayed MIBG scan reflects 
the neuronal uptake of MIBG more specifically. 
Therefore, myocardial MIBG uptake was assessed 15 
min and 3-4 h postinjection.
18
A decreased MIBG uptake suggests the loss or 
destruction of cardiac sympathetic nerve endings.
19 Lewy 
bodies are found in the hypothalamus, intermediolateral 
cell columns of the spinal cord, and sympathetic ganglia 
in patients with PD.
20,21,22 It is known that central or 
preganglionic lesions, such as those in the cardiovascular 
autonomic center of the ventrolateral medullar or inter-
mediolateral cell column of the spinal cord, contribute to 
the dysautonomia of MSA.
23,24 Orimo et al. reported that 
tyrosine-hydroxylase-immunoreactive sympathetic nerve 
fibers in the myocardium are reduced markedly in PD 
patients in contrast to those in both MSA and normal 
controls, suggesting that the involvement of postgan-
glionic sympathetic nerve fibers, including sympathetic 
nerves in the myocardium, explains the difference in the 
uptake of MIBG.
25 Cohen et al. hypothesized that in 
MSA, dysfunction of the postganglionic sympathetic 
fibers is caused by the trans-synaptic effects of the 
preganglionic lesion,
26 and we postulate that this 
mechanism explains the reduced cardiac uptake of 
MIBG.
In recent studies, the cardiac-MIBG H/M ratio in 
patients with CBD was found to be within the range of 
normal controls, and tyrosine-hydroxylase-reactive 
sympathetic nerves in the myocardium appeared Journal of Clinical Neurology: Vol. 2, No. 1, 2006
- 56 -
normal.
27,28 Although the number of CBD patients in our 
study was small, the cardiac-MIBG H/M ratio in CBD 
patients was within the control range.
Different drugs, such as neuroleptics, calcium channel 
blockers, and dopamine-depleting agents, have different 
effects on dopaminergic receptors, which influence the 
clinical outcome of patients with DIP. Tolosa et al.
29 
divided DIP patients into three subgroups: 1) full, long- 
lasting recovery of DIP with no subsequent development 
of PD (i.e., DIP is unrelated to PD); 2) persistence and 
eventual worsening of parkinsonism after discontinuation 
of the offending drug (DIP unmasks PD); and 3) full 
remission of DIP after withdrawal of the offending drug 
with the subsequent reappearance of parkinsonism (DIP 
antedates PD). Since the treatment and prognosis of DIP 
antedating PD are clearly different from those of DIP 
unrelated to PD, the differentiation of these disorders is 
very important. In this study, DIP patients who had a 
cardiac-MIBG H/M ratio in the normal range improved 
markedly or had their symptoms resolve within several 
weeks of withdrawal of the offending drug. In these 
patients, the DIP was very probably unrelated to PD. 
The two patients whose cardiac-MIBG H/M ratios were 
within the range of PD patients still had parkinsonian 
symptoms after withdrawal of the offending drug and 
these symptoms were improved with levodopa treatment. 
We postulate that these two patients had subclinical PD. 
Unfortunately, we did not perform functional imaging on 
these patients to evaluate the nigrostriatal system, so we 
cannot conclude that these patients definitely had 
subclinical PD.
Various drugs have been reported to influence 
cardiac-MIBG uptake. Haloperidol decreases MIBG 
uptake at very highly concentrations, albeit at concent-
rations far above therapeutic doses.
30 Cilnidipine, a 
third-generation dihydropyridine-based calcium antagonist, 
is reported to enhance cardiac-MIBG uptake, which 
would lead to a falsely elevated MIBG uptakes; how-
ever, this effect is likely minimal because the increase 
in the H/M ratio after cilnidipine treatment is very small 
(~0.1).
31 Chlorpromazine and perphenazine are expected 
to interfere with cardiac-MIBG uptake, although there is 
no direct evidence of this effect.
32 Finally, there are no 
reports of interactions between levosulpiride, metoclo-
pramide, risperidone, and MIBG. Therefore, we believe 
that the influence of any such drugs on MIBG uptake 
was trivial in the present study.
This study is limited by the absence of pathological 
diagnoses and the absence of functional imaging to 
evaluate the presynaptic and postsynaptic dopaminergic 
neurons of the nigrostriatal dopaminergic system. There-
fore, the threshold, sensitivity, and specificity values 
obtained in our study may be inaccurate. However, we 
suggest that cardiac-MIBG SPECT is a useful method 
for differentiating PD from atypical parkinsonism and 
for detecting subclinical PD within DIP patients.
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